Connect to other sites within the UBM Medica Network
Modern Breast Cancer Staging Should Include Tumor Biology
According to a presentation at MBCC, modern breast cancer staging systems should include grade, estrogen receptor status, and possibly other biologic markers.
Surveillance Risky in Intermediate-Risk Prostate Cancer?
Intermediate-risk prostate cancer patients managed with surveillance had worse outcomes compared with low-risk prostate cancer patients managed with surveillance.
High-Dose Radiotherapy Fails to Improve Prostate Cancer Survival
High-dose radiation therapy did not improve overall survival compared with the standard dose in stage II localized prostate cancer, but did show some benefits.
Eribulin Dose-Modification May Allow for Better Outcomes
Women with breast cancer who received first-line eribulin were able to stay on treatment longer and had better outcomes when they received dose modifications.
MRI Screening for Breast Cancer
As part of our MBCC coverage we discuss MRI screening for breast cancer in patients who carry a BRCA mutation or have a first-degree relative who is a BRCA carrier.
Pain Control an Important Aspect of Breast Cancer Treatment
As part of our MBCC coverage, we discuss how physicians can improve the patient experience through pain control both during and after breast cancer treatment.
Hormone Therapy Adherence in Breast Cancer Linked to Race, Income
Economic factors, including household income, and racial disparities both play a role in the adherence to hormonal therapy in breast cancer patients.
Unlikelihood of Cure Did Not Reduce Chemo Use at End of Life
Patients with lung and colorectal cancer who understood that chemotherapy would not cure them were no less likely to receive chemotherapy at the end of life.
Phone Counseling Improves QOL in Cervical Cancer Survivors
Cervical cancer survivors saw improvements in self-reported quality-of-life outcomes with a psychosocial telephone counseling intervention, according to a new study.
Higher-Risk Prostate Cancer on the Rise?
A large retrospective analysis suggests the number of patients diagnosed with intermediate- and high-risk prostate cancer has increased since 2011.
By clicking Accept, you agree to become a member of the UBM Medica Community.